Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Kymera Therapeutics Inc (KYMR) USD0.0001

Sell:$52.00 Buy:$73.37 Change: $2.46 (3.91%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Change: $2.46 (3.91%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Change: $2.46 (3.91%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kymera Therapeutics Inc is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation platform, Pegasus, allows it to discover selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body. Its initial programs include IRAK4, IRAKIMiD, and STAT3. The Company is developing its IRAK4 program for the treatment of a broad set of immunology-inflammation diseases, including hidradenitis suppurativa (HS), atopic dermatitis (AD) and rheumatoid. Its programs are focused on a single critical signaling node within the genetically and clinically validated IL-1R/TLR and JAK/STAT pathways.

Contact details

200 Arsenal Yards Blvd.
Suite 230, 2Nd Floor
United States
+1 (857) 2855314

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.21 billion
Shares in issue:
51.04 million
United States
US dollar

Key personnel

  • Nello Mainolfi
    President, Chief Executive Officer, Co-Founder, Director
  • Bruce Jacobs
    Chief Financial Officer
  • Richard Chesworth
    Chief Scientific Officer
  • Elaine Caughey
    Chief Business Officer
  • Jared Gollob
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.